<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01633502</url>
  </required_header>
  <id_info>
    <org_study_id>DanShock-01</org_study_id>
    <nct_id>NCT01633502</nct_id>
  </id_info>
  <brief_title>Danish Cardiogenic Shock Trial</brief_title>
  <acronym>DanShock</acronym>
  <official_title>Effects of Advanced Mechanical Circulatory Support in Patients With ST Segment Elevation Myocardial Infarction Complicated by Cardiogenic Shock. The Danish Cardiogenic Shock Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital Skejby</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiogenic shock a serious complication of a heart attack (myocardial infarction). Despite
      rapid invasive treatment, circulatory support using positive inotropes and mechanical support
      with intra-aortic balloon counterpulsation (IABP), and evaluation of several new treatments
      during the last decade, the mortality in patients with cardiogenic shock still exceeds 50%.
      An alternative to current management is restoration of the volume of blood pumped by the
      heart (cardiac output) using a ventricular assist device. In the acute setting this is
      difficult but can be done using the Impella device which is a catheter-based, axial flow pump
      that pumps blood directly from the left ventricle into the circulation thereby restoring
      blood flow to the failing organs. In 2012 a more powerful Impella has been introduced that is
      able to deliver 3.5l/min (approximately 75% of a normal cardiac output). The hypothesis of
      the current study is to reduce mortality and morbidity of patients with cardiogenic shock
      using the Impella CP. The study will be carried out as a randomized multicenter study where
      eligible patients will be randomized to receive conventional circulatory support or support
      with the Impella device and inotropic support if needed. A total of 360 patients are planned
      to be enrolled, and the primary endpoint will be death.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>minimum follow-up 6 months</time_frame>
    <description>Death from all causes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>minimum follow-up 6 months</time_frame>
    <description>Major cardiovascular events, death, cardiac transplant, escalation to permanent left ventricular assist device, re-hospitalization for heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined safety</measure>
    <time_frame>6 months</time_frame>
    <description>Combined safety comprising major bleeding, vascular complications, and significant hemolysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>6 months</time_frame>
    <description>glomerular filtration rate, use dialysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SIRS</measure>
    <time_frame>1 months</time_frame>
    <description>Development of systemic inflammatory response syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economics</measure>
    <time_frame>6 months</time_frame>
    <description>Cost of treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamics</measure>
    <time_frame>7 days</time_frame>
    <description>Cardiac power index, lactate clearance, pulmonary capillary wedge pressure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Cardiogenic Shock Acute</condition>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Conventional circulatory support</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized to conventional circulatory support.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Impella</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to Impella CP</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional circulatory support</intervention_name>
    <description>Control group treated with conventional circulatory support and observed in intensive care unit for a minimum of 48 hrs.</description>
    <arm_group_label>Conventional circulatory support</arm_group_label>
    <other_name>Conventional circulatory support will be employed according to enrolling sites usual management.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Impella CP</intervention_name>
    <description>Control group treated with Impella CP for a minimum of 48 hrs.</description>
    <arm_group_label>Impella</arm_group_label>
    <other_name>Impella CP, Abiomed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ST segment elevation myocardial infarction of less than 36 hours' duration, confirmed
             by new onset ST-segment elevation, or emergency angiography demonstrating acute
             occlusion of coronary artery, and

          2. Cardiogenic shock of less than 24 hours' duration, confirmed by:

               -  peripheral signs of tissue hypoperfusion (arterial blood lactate ≥2.5mmol/l
                  and/or SvO2 &lt;55% with a normal PaO2) and

               -  systolic blood pressure less than 100mmHg and/or need for vasopressor therapy
                  (dopamine/ norepinephrine or epinephrine), and

          3. Left ventricular ejection fraction of less than 45% visually estimated or by wall
             motion score index &gt;1,6.

        Exclusion Criteria:

          1. Other causes of shock (hypovolemia, hemorrhage, sepsis, pulmonary embolism or
             anaphylaxis).

          2. Shock due to mechanical complication to myocardial infarction (papillary muscle
             rupture, rupture of the ventricular septum or rupture of free wall).

          3. Severe aorta valve regurgitation/stenosis.

          4. Predominant right ventricular failure.

          5. Out of hospital cardiac arrest with persistent Glasgow coma scale &lt;8 after return of
             spontaneous circulation.

          6. Shock duration&gt;24 hours.

          7. Known heparin intolerance.

          8. Already established mechanical circulatory support

          9. Do not resuscitate wish.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob E Moller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Center, Copenhagen University Hospital Rigshospitalet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans Eiskjær, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anders Junker, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiology, Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Hassager, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiology, Copenhagen University Hospital Gentofte</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Shaefer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nikos Werner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Bonn</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacob E Moller, MD</last_name>
    <phone>-4566113333</phone>
    <email>jem@dadlnet.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hans Eiskjær, MD</last_name>
    <email>heis@dadlnet.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital Skejby</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Eiskjær, MD</last_name>
      <email>Heis@dadlnet.dk</email>
    </contact>
    <investigator>
      <last_name>Hans Eiskjær, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian J Therkelsen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob E Moller, MD</last_name>
      <phone>+4535450887</phone>
      <email>jem@dadlnet.dk</email>
    </contact>
    <investigator>
      <last_name>Christian Hassager, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Engstrøm, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lene Holmvang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matias G Lindholm, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Junker, MD</last_name>
      <email>anders.junker@ouh.regionsyddanmark.dk</email>
    </contact>
    <investigator>
      <last_name>Anders Junker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisette O Jensen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henrik Schmidt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Malte Sinning, Professor</last_name>
      <email>jan-malte.sinning@ukbonn.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dresden University Hospital</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Linke, Professor</last_name>
      <email>axel.linke@herzzentrum-dresden.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Düsseldorf University Hospital</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ralf Westenfeld, Professor</last_name>
      <email>Ralf.Westenfeld@med.uni-duesseldorf.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Schaefer, Professor</last_name>
      <email>Schaefer.Andreas@mh-hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jena University Hospital</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Schulze, Professor</last_name>
      <email>Christian.Schulze@med.uni-jena.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 28, 2012</study_first_submitted>
  <study_first_submitted_qc>June 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2012</study_first_posted>
  <last_update_submitted>May 30, 2019</last_update_submitted>
  <last_update_submitted_qc>May 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Jacob Moller</investigator_full_name>
    <investigator_title>Professor in Cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

